Integrative physiology of pneumonia
LJ Quinton, AJ Walkey, JP Mizgerd - Physiological reviews, 2018 - journals.physiology.org
Pneumonia is a type of acute lower respiratory infection that is common and severe. The
outcome of lower respiratory infection is determined by the degrees to which immunity is …
outcome of lower respiratory infection is determined by the degrees to which immunity is …
A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens
CC Daniels, PD Rogers… - The Journal of Pediatric …, 2016 - meridian.allenpress.com
This review describes development of currently available pneumococcal vaccines, provides
summary tables of current pneumococcal vaccine recommendations in children and adults …
summary tables of current pneumococcal vaccine recommendations in children and adults …
Lung-resident memory B cells protect against bacterial pneumonia
KA Barker, NS Etesami, AT Shenoy… - The Journal of …, 2021 - Am Soc Clin Investig
Lung-resident memory B cells (BRM cells) are elicited after influenza infections of mice, but
connections to other pathogens and hosts—as well as their functional significance—have …
connections to other pathogens and hosts—as well as their functional significance—have …
Reverse vaccinology: developing vaccines in the era of genomics
A Sette, R Rappuoli - Immunity, 2010 - cell.com
The sequence of microbial genomes made all potential antigens of each pathogen available
for vaccine development. This increased by orders of magnitude potential vaccine targets in …
for vaccine development. This increased by orders of magnitude potential vaccine targets in …
Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens
NPH Knudsen, A Olsen, C Buonsanti, F Follmann… - Scientific reports, 2016 - nature.com
The majority of vaccine candidates in clinical development are highly purified proteins and
peptides relying on adjuvants to enhance and/or direct immune responses. Despite the …
peptides relying on adjuvants to enhance and/or direct immune responses. Despite the …
Structure and dynamics of the pan-genome of Streptococcus pneumoniae and closely related species
Background Streptococcus pneumoniae is one of the most important causes of microbial
diseases in humans. The genomes of 44 diverse strains of S. pneumoniae were analyzed …
diseases in humans. The genomes of 44 diverse strains of S. pneumoniae were analyzed …
Accelerating next-generation vaccine development for global disease prevention
WC Koff, DR Burton, PR Johnson, BD Walker, CR King… - Science, 2013 - science.org
Background Vaccines have provided some of the greatest successes in the history of
medicine, including the eradication of smallpox, the near eradication of polio, and the …
medicine, including the eradication of smallpox, the near eradication of polio, and the …
From empiricism to rational design: a personal perspective of the evolution of vaccine development
E De Gregorio, R Rappuoli - Nature Reviews Immunology, 2014 - nature.com
Vaccination, which is the most effective medical intervention that has ever been introduced,
originated from the observation that individuals who survived a plague or smallpox would …
originated from the observation that individuals who survived a plague or smallpox would …
A matter of life and death: cell wall homeostasis and the WalKR (YycGF) essential signal transduction pathway
Summary The WalK/WalR (aka YycG/YycF) two‐component system (TCS), originally
identified in Bacillus subtilis, is very highly conserved and specific to low G+ C Gram …
identified in Bacillus subtilis, is very highly conserved and specific to low G+ C Gram …
Fighting bacterial infections—future treatment options
J Fernebro - Drug Resistance Updates, 2011 - Elsevier
This review summarizes ongoing research aimed at finding novel drugs as alternatives to
traditional antibiotics. Anti-virulence approaches, phage therapy and therapeutic antibodies …
traditional antibiotics. Anti-virulence approaches, phage therapy and therapeutic antibodies …